TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31504541

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schizophrenia liability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglycerides in medium very-low-density lipoprotein (VLDL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglycerides in large VLDL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 0
Study: 28157791

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (10 mL of liposome bupivacaine 133 mg) added to 5 mL of 0.25% bupivacaine HCl
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard bupivacaine (15 mL of 0.25% bupivacaine HCl) alone
Number of subjects: 52
Study: 27085587

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study: 24332192

Group type: EXPERIMENTAL
Intervention: Home-based physical activity program (HB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Group exercise program (G)
Number of subjects: 76
Study: 21823282

Group type: EXPERIMENTAL
Intervention: Acupuncture at Tianshu (ST 25) and Dachangshu (BL 25), once daily for 4 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trimebutine Maleate, 2 capsules, 3 times per day for 4 weeks.
Number of subjects: 40
Study: 19141778

Group type: EXPERIMENTAL
Intervention: Double testing with cytology and type-specific HPV persistence
Number of subjects: 6257

Group type: EXPERIMENTAL
Intervention: Primary screening with HPV DNA testing followed by cytological triage and repeat HPV DNA testing
Number of subjects: 6257

Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 6257
Study: 17607003

Group type: EXPERIMENTAL
Intervention: C-allele at low levels of endotoxin exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-allele at high levels of endotoxin exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-allele homozygotes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other two genotypes (not specified)
Number of subjects: 0
Study: 14709946

Group type: EXPERIMENTAL
Intervention: Sertraline (Zoloft) 50 to 200 mg/d
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11427227

Group type: EXPERIMENTAL
Intervention: Raised lipoprotein (a) levels at baseline
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Raised lipoprotein (a) levels at baseline after adjustment for baseline cardiovascular disease and other risk factors
Number of subjects: 1592
Study: 9732416

Group type: EXPERIMENTAL
Intervention: Seeded grafts with transplanted microvessel cells
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nonseeded grafts
Number of subjects: 9
Study: 8050691

Group type: EXPERIMENTAL
Intervention: Presence of vascular invasion
Number of subjects: 106

Group type: COMPARATOR
Intervention: Absence of vascular invasion
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Tumour vascular invasion
Number of subjects: 106
Study: 2724108

Group type: EXPERIMENTAL
Intervention: Xylocaine (lidocaine hydrochloride) administered as a posterior tibial block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sensorcaine (bupivacaine hydrochloride) administered as a posterior tibial block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nerve blockade of remaining nerves of the foot
Number of subjects: 50
Study: 31843791

Group type: EXPERIMENTAL
Intervention: PPV with macular ILM peeling
Number of subjects: 60

Group type: COMPARATOR
Intervention: PPV alone (conventional treatment)
Number of subjects: 60
Study: 30977904

Group type: EXPERIMENTAL
Intervention: Active tDCS (2.0 milliamps) combined with MBRP
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham tDCS (0.0 milliamps) combined with MBRP
Number of subjects: 84
Study: 28427336

Group type: EXPERIMENTAL
Intervention: Home modification intervention provided by an occupational therapist in addition to usual care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (continued services from the area agency on aging)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Home modification intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Implementation component of the study
Number of subjects: 300
Study: 25442169

Group type: EXPERIMENTAL
Intervention: Small-sided games
Number of subjects: 9

Group type: COMPARATOR
Intervention: Stationary cycling
Number of subjects: 9
Study: 22505295

Group type: EXPERIMENTAL
Intervention: MRI (early scan of the wrist, discharged if no injury)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (reassessment in clinic)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MRI (early scan of the wrist)
Number of subjects: 84
Study: 21821221

Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) curriculum
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional curriculum (Control)
Number of subjects: 26
Study: 19497079

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine plus artesunate (SP/AS)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate (AQ/AS)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine plus artesunate (SP/AS) and Amodiaquine plus artesunate (AQ/AS)
Number of subjects: 296
Study: 16454979

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (loading dose of 300 mg aspirin and 300 mg clopidogrel, then 100 mg aspirin and 75 mg clopidogrel per day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Aspirin alone (loading dose of 300 mg aspirin, then 100 mg per day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers on no medications)
Number of subjects: 115
Study: 12641517

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 11056333

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 769

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 769
Study: 8957697

Group type: EXPERIMENTAL
Intervention: Oral Vitamin E treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study: 1533427

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels at study entry
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: ANP value greater than 200 pmol/L
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: History of CHF in the previous year
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Stratification of cohort by ANP levels and history of CHF
Number of subjects: 331
Study: 2410520

Group type: EXPERIMENTAL
Intervention: Thiazina (combination tablet of thiacetazone and INH) daily for 12 months
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Thiazina daily for 12 months plus rifampin daily during months 1 and 7
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Rifampin daily during months 1 and 7 but no Thiazina
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group (dapsone monotherapy)
Number of subjects: 806
Study: 29094283

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for depression and anxiety
Number of subjects: 115

Group type: COMPARATOR
Intervention: Comparison group (no CBT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Non-CBT group
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All groups (CBT, Comparison, Non-CBT)
Number of subjects: 115
Study: 27768695

Group type: EXPERIMENTAL
Intervention: CCX168 (30 mg orally, twice daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CCX168 (1 to 100 mg)
Number of subjects: 48
Study: 24456286

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPT; 20 μg s.c.) for 6 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 21
Study: 23321196

Group type: EXPERIMENTAL
Intervention: Tolvaptan 3.75 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg/day
Number of subjects: 0
Study: 20837928

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atorvastatin 0, 5, or 50 μmol/L ex vivo
Number of subjects: 42
Study: 18432253

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 30
Study: 16452128

Group type: EXPERIMENTAL
Intervention: Group recruitment method after lectures
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Individual recruitment by researchers
Number of subjects: 2500
Study: 12753596

Group type: EXPERIMENTAL
Intervention: Four-layer bandage system (Profore)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Two-layer bandage system (Surepress)
Number of subjects: 112
Study: 10440462

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 3,600 mg daily in three divided doses)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 69
Study: 8773038

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 2276107

Group type: EXPERIMENTAL
Intervention: Oral care protocol A
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral care protocol B
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reinforcement of oral care instructions and nursing assessments
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peripheral white blood cell count
Number of subjects: 18
Study: 427401

Group type: EXPERIMENTAL
Intervention: Brief care (experimental group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 127
Study: 31939712

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobotomy (ATLo)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATLe)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 31121913

Group type: EXPERIMENTAL
Intervention: Euglena gracilis EOD1BM ingestion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28477678

Group type: EXPERIMENTAL
Intervention: Nurse-led group clinic intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 35
Study: 26471180

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open surgery (OG)
Number of subjects: 70
Study: 22883421

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg/kg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 mcg/kg
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 21160058

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18534086

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: BIS 0.5 mg twice daily (b.i.d.)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: BIS 0.25 mg b.i.d. and 0.5 mg b.i.d.
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: All BIS regimens
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: BIS 0.25 mg once daily (q.d.)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: BIS 0.5 mg q.d.
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: BIS 1.0 mg q.d.
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1018
Study: 17242413

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of 0.2% ropivacaine hydrochloride (10 mL/h without bolus)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (10 mL of 0.2% ropivacaine hydrochloride per hour with 10-mL bolus)
Number of subjects: 50
Study: 12598885

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 900 mg
Number of subjects: 167
Study: 11396782

Group type: COMPARATOR
Intervention: Hypertensive subjects
Number of subjects: 0
Study: 9545995

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day, adjusted to 6.4 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clozapine (300 mg/day, adjusted to 291.2 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 8004600

Group type: EXPERIMENTAL
Intervention: Mammography in the BCDDP (1970s)
Number of subjects: 93471

Group type: COMPARATOR
Intervention: Mammography in the HIP study (1960s)
Number of subjects: 93471

Group type: EXPERIMENTAL
Intervention: Annual two-view mammography plus clinical breast examination
Number of subjects: 93471

Group type: EXPERIMENTAL
Intervention: Comparison of types, sizes, stage distributions, and survival rates
Number of subjects: 93471
Study: 2574081

Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control infusion (0.9% saline)
Number of subjects: 9
Study: 819341

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Diamox)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control persons (not specified)
Number of subjects: 25
Study: 7411761

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate or estolate, 500 mg orally every six hours for five days (13 patients)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Crystalline aqueous penicillin G potassium, 1 million units intravenously every three hours for three days (10 patients)
Number of subjects: 23
Study: 31567921

Group type: EXPERIMENTAL
Intervention: Same-day dose of 4 L polyethylene glycol
Number of subjects: 339

Group type: COMPARATOR
Intervention: Split-dose of 4 L polyethylene glycol (2 L at 9:00 PM the day before and 2 L at 7:00 AM or 10:00 AM)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Split-dose of 4 L polyethylene glycol
Number of subjects: 339
Study: 29385967

Group type: EXPERIMENTAL
Intervention: Clinician-led chronic disease self-management support (CDSMS) program
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (positive attention only)
Number of subjects: 254
Study: 27004474

Group type: EXPERIMENTAL
Intervention: e‐SBI (n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (n=62)
Number of subjects: 123
Study: 24580388

Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance (TIVA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol induction and sevoflurane maintenance (MIXED)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane induction and maintenance (SEVO)
Number of subjects: 60
Study: 22298852

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study: 20817133

Group type: EXPERIMENTAL
Intervention: Prior non-fearful experiences with the stimulus (preexposure group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fear conditioning (paired presentations of a geometric figure and electric shock)
Number of subjects: 0
Study: 17993094

Group type: EXPERIMENTAL
Intervention: Soft Seal mask
Number of subjects: 60

Group type: COMPARATOR
Intervention: LMA Classic mask
Number of subjects: 60
Study: 15987330

Group type: EXPERIMENTAL
Intervention: Educational experience at a women's safe shelter
Number of subjects: 36

Group type: COMPARATOR
Intervention: Workshop seminar alone (control)
Number of subjects: 36
Study: 12185558

Group type: EXPERIMENTAL
Intervention: Oral artemisinin 500 mg daily for 3 days followed by oral mefloquine 750 mg on day 4
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oral artemisinin 500 mg daily for 3 days plus oral mefloquine 750 mg on day 1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single 750-mg oral dose of mefloquine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Artemisinin alone for the first 3 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Artemisinin and mefloquine combination
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mefloquine alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mefloquine after a 3-day regimen of artemisinin
Number of subjects: 42
Study: 9455524

Group type: EXPERIMENTAL
Intervention: Azithromycin, 250 mg daily
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Azithromycin, 1,000 mg weekly
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg daily
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 7895002

Group type: EXPERIMENTAL
Intervention: Parkinson's disease subjects
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study: 1695877

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of terfenadine and flurbiprofen
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All active drug days (terfenadine, flurbiprofen, combination)
Number of subjects: 8
Study: 320477

Group type: EXPERIMENTAL
Intervention: Antibiotics plus daily granulocyte transfusions from ABO-matched donors
Number of subjects: 31

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 31
Study: 30218709

Group type: EXPERIMENTAL
Intervention: VisCubeSX VR anatomic model
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional independent study curriculum
Number of subjects: 31
Study: 28950190

Group type: EXPERIMENTAL
Intervention: Transumbilical route (TU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lateral transabdominal route (TA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 25537197

Group type: EXPERIMENTAL
Intervention: AT LISA 809M IOL
Number of subjects: 188

Group type: COMPARATOR
Intervention: ReSTOR SN6AD1 IOL
Number of subjects: 188
Study: 23422376

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone (10 to 20 mg as required up to a maximum of 40 mg/d)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg every 4 to 8 hours to a maximum of 20 mg/d)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 376

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 376
Study: 20615933

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (starting dose 50 mg eq., flexible dosing of 25, 50, 75, or 100 mg eq.)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 388
Study: 19439457

Group type: EXPERIMENTAL
Intervention: 60 mg Fe with 400 microg folic acid
Number of subjects: 180

Group type: COMPARATOR
Intervention: 30 mg Fe with 400 microg folic acid
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MuMS; 30 mg Fe, 400 microg folic acid, and other micronutrients)
Number of subjects: 180
Study: 16460693

Group type: EXPERIMENTAL
Intervention: 20 mg/day citalopram
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15057843

Group type: EXPERIMENTAL
Intervention: Anterior capsulotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior cingulotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcaudate tractotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limbic leucotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central lateral thalamotomy/anterior medial pallidotomy
Number of subjects: 0
Study: 11680557

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined individual and family therapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 114
Study: 9326834

Group type: EXPERIMENTAL
Intervention: Xanomeline (25 mg t.i.d., 50 mg t.i.d., 75 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8145176

Group type: COMPARATOR
Intervention: Alprazolam (1 mg decrease every 3-7 days)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Alprazolam (long-term treatment for 5-12 months)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Alprazolam (tapering and discontinuation)
Number of subjects: 251
Study: 2427808

Group type: EXPERIMENTAL
Intervention: 90 mg/day nicardipine for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10(-4) M nicardipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10(-8) M nicardipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10(-6) M nicardipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10(-4) M nicardipine, 10(-8) M nicardipine, 10(-6) M nicardipine
Number of subjects: 8
Study: 31405765

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg QD for 5 weeks
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg QD for 5 weeks
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg QD for 5 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 361
Study: 29284443

Group type: EXPERIMENTAL
Intervention: BRIA psychotherapy sessions
Number of subjects: 220

Group type: COMPARATOR
Intervention: BWA only
Number of subjects: 220
Study: 25265545

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Support and discussion control group
Number of subjects: 101
Study: 23860985

Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of stress-dose hydrocortisone (300 mg daily for 7 days maximum)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Saline placebo plus epinephrine (1 mg/CPR cycle)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Saline placebo plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of saline placebo
Number of subjects: 268